http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
-
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
-
WAVE Life Sciences (WVE) Amends Collaboration with Takeda
-
Wave Life Sciences and Takeda Amend CNS Collaboration
-
Wave Life Sciences and Takeda Amend CNS Collaboration
-
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy
-
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy
-
WAVE Life Sciences (WVE) Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
-
Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
-
Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
-
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
-
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
-
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
-
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
-
Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
-
Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
-
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences
-
Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences
-
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021
-
Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021
-
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
-
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
-
WAVE Life Sciences (WVE) Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
-
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
-
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
-
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
-
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
-
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
-
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
-
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
-
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
-
Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
-
Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
-
Wave Life Sciences (WVE) Provides Update on Phase 1b/2a PRECISION-HD Trials
-
Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials
-
Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials
-
Wave Life Sciences to Present at the Third Annual Stifel CNS Day
-
Wave Life Sciences to Present at the Third Annual Stifel CNS Day
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
-
Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference
-
Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference
-
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
-
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications

